Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Juhi Asad, Allyson F. Jacobson, Alison Estabrook, Sharon Rosenbaum Smith, Susan K. Boolbol, Sheldon M. Feldman, Michael P. Osborne, Kwadwo Boachie-Adjei, Wendy Twardzik, Paul I. Tartter

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

Original languageEnglish (US)
Pages (from-to)527-529
Number of pages3
JournalAmerican Journal of Surgery
Volume196
Issue number4
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Breast Neoplasms
Recurrence
Estrogen Receptors
Neoplasms
Lymph Nodes
Therapeutics
Software
Retrospective Studies
Drug Therapy
Genes

Keywords

  • 21-gene
  • Assay
  • Breast cancer
  • Management
  • Recurrence score

ASJC Scopus subject areas

  • Surgery

Cite this

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? / Asad, Juhi; Jacobson, Allyson F.; Estabrook, Alison; Smith, Sharon Rosenbaum; Boolbol, Susan K.; Feldman, Sheldon M.; Osborne, Michael P.; Boachie-Adjei, Kwadwo; Twardzik, Wendy; Tartter, Paul I.

In: American Journal of Surgery, Vol. 196, No. 4, 01.10.2008, p. 527-529.

Research output: Contribution to journalArticle

Asad, J, Jacobson, AF, Estabrook, A, Smith, SR, Boolbol, SK, Feldman, SM, Osborne, MP, Boachie-Adjei, K, Twardzik, W & Tartter, PI 2008, 'Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?', American Journal of Surgery, vol. 196, no. 4, pp. 527-529. https://doi.org/10.1016/j.amjsurg.2008.06.021
Asad, Juhi ; Jacobson, Allyson F. ; Estabrook, Alison ; Smith, Sharon Rosenbaum ; Boolbol, Susan K. ; Feldman, Sheldon M. ; Osborne, Michael P. ; Boachie-Adjei, Kwadwo ; Twardzik, Wendy ; Tartter, Paul I. / Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. In: American Journal of Surgery. 2008 ; Vol. 196, No. 4. pp. 527-529.
@article{e1a672c232d440768689bf779f83fd7e,
title = "Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?",
abstract = "Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44{\%} of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44{\%} of patients was altered as a consequence of Oncotype DX RS.",
keywords = "21-gene, Assay, Breast cancer, Management, Recurrence score",
author = "Juhi Asad and Jacobson, {Allyson F.} and Alison Estabrook and Smith, {Sharon Rosenbaum} and Boolbol, {Susan K.} and Feldman, {Sheldon M.} and Osborne, {Michael P.} and Kwadwo Boachie-Adjei and Wendy Twardzik and Tartter, {Paul I.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.amjsurg.2008.06.021",
language = "English (US)",
volume = "196",
pages = "527--529",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

AU - Asad, Juhi

AU - Jacobson, Allyson F.

AU - Estabrook, Alison

AU - Smith, Sharon Rosenbaum

AU - Boolbol, Susan K.

AU - Feldman, Sheldon M.

AU - Osborne, Michael P.

AU - Boachie-Adjei, Kwadwo

AU - Twardzik, Wendy

AU - Tartter, Paul I.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

AB - Background: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. Methods: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. Results: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. Conclusions: Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

KW - 21-gene

KW - Assay

KW - Breast cancer

KW - Management

KW - Recurrence score

UR - http://www.scopus.com/inward/record.url?scp=52049089470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049089470&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2008.06.021

DO - 10.1016/j.amjsurg.2008.06.021

M3 - Article

C2 - 18809056

AN - SCOPUS:52049089470

VL - 196

SP - 527

EP - 529

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -